Drug Profile
AK 01
Alternative Names: AK-01; Aur A Kinase Inhibitor - Eli Lilly and Company; Erbumine; LY-3295668; LY3295668 ErbumineLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; National Cancer Institute (USA)
- Class Antineoplastics
- Mechanism of Action Aurora kinase A inhibitors; Cell division inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer; Solid tumours
- No development reported Breast cancer; Neuroblastoma; Small cell lung cancer
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Neuroblastoma(Combination therapy, In children, Second-line therapy or greater, In adults) in Australia (PO, Capsule)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Neuroblastoma(Combination therapy, In children, Second-line therapy or greater, In adults) in Belgium (PO, Capsule)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Neuroblastoma(Combination therapy, In children, Second-line therapy or greater, In adults) in Canada (PO, Capsule)